Eli Lilly widening lead over Novo Nordisk
The thesis argued is that Eli Lilly is establishing single-player market dominance in GLP-1 weight loss therapies through superior trial efficacy stories and product execution over Novo Nordisk.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.